We report on multicolor excitation experiments with color centers in hexagonal boron nitride at cryogenic temperatures. We demonstrate controllable optical switching between bright and dark states of color centers emitting around 2 eV. Resonant, or quasi-reso…
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
Just as cloning in biology allows for the creation of one or more replicas of the exact same genes, seeded growth in chemistry can produce a very large metal foil with the exact same surface texture as that of a seeded one. Seeded growth is very popular in sy…
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2020 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to.
Find all the information and dates you need for marketing conferences this year.
ADMA Biologics (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced that it has received another Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV™. ADMA is the exclusive owner of intellectual property encompassing certain immunotherapeutic, immunoglobulin (IG & IVIG) compositions for the prevention and treatment of a wide variety of respiratory infections, including certain strains of coronavirus.
The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally to include 10 plasma companies, and now also includes global organizations from outside the plasma industry who are providing vital support to encourage more people to donate plasma.
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,.
The companies, however, returned two-thirds of the loans they received under the paycheck protection program.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / ADMA Biologics, Inc. (NASDAQ:ADMA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:30 ...
The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally t…
The shares were issued pursuant to the full exercise of the underwriters’ overallotment option in connection with ADMA’s previously announced underwritten public offering of 23,500,000 shares of its common stock. The gross proceeds from the exercise of the overallotment option were approximately $12.3 million, bringing the total gross proceeds to ADMA from the offering to approximately $94.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
The origin of crystal-size-dependent adsorption behavior of flexible metal–organic frameworks is increasingly studied. In this contribution, we probe the solid–fluid interactions of DUT-49 crystals of different size by in situ 129Xe NMR spectroscopy at 200 K.…
This Article describes the design, synthesis, and analysis of a new class of polymer that is capable of depolymerizing continuously, completely, and cleanly from head to tail when a detection unit on the head of the polymer is exposed to a specific applied si…
ETH researchers have developed a new method in which they use light to draw patterns of molecules that guide living cells. The approach allows for a closer look at the development of multicellular organisms—and in the future may even play a part in novel ther…
A soft, stretchable experimental battery developed by researchers at the Stanford School of Engineering uses a special type of plastic to store power, which the developers say is safer than the flammable formulations used in conventional batteries.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.
Professor Zhan Xiaowei's group from the College of Engineering at Peking University made new progress in non-fullerene acceptors for organic solar cells (OSCs). They developed a new fluorinated fused-ring electron acceptor (FREA) with 3D stacking and exciton …
Liposomal drug delivery for cancer therapy can be limited due to drug leakage in circulation. Here, we develop a new method to enhance the stability of actively loaded liposomal doxorubicin (DOX) through embedding a stiff nanobowl in the liposomal water cavit…
Multiple fused pentagon–heptagon pairs are frequently found as defects at the grain boundaries of the hexagonal graphene lattice and are suggested to have a fundamental influence on graphene-related materials. However, the construction of sp2-carbon skeletons…
The "Global Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
Q1 2020 ADMA Biologics Inc Earnings Call
RAMSEY, N.J. and BOCA RATON, Fla., May 27, 2020 -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated.
At this time, I would like to introduce Mr. Sam Martin, Managing Director at Argot Partners, ADMA's Investor Relations firm. Welcome everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the first quarter 2020.
Achieved Fourth Quarter 2019 Total Revenues of $12.0 Million, a 197% Increase Over Fourth Quarter 2018 Achieved Full Year 2019 Total Revenues of $29.3 Million, a 73% Increase.
ADMA is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA is seeking US citizens who have recovered from coronavirus (SARS-CoV-2) or COVID-19, to donate plasma, which can be used to produce an immune globulin to potentially help infected patients with COVID-19.
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
"Metabolic health really matters. It is the common thread that links all of these chronic diseases." — Peter Attia The post #111 – AMA #14: What lab tests can (and cannot) inform us about our overall objective of longevity appeared first on Peter Attia.
One of the biggest stories of last week was how ADMA Biologics, Inc. (NASDAQ:ADMA) shares plunged 30% in the week...
Q4 2019 ADMA Biologics Inc Earnings Call
Investors who take an interest in ADMA Biologics, Inc. (NASDAQ:ADMA) should definitely note that the Co-Founder, Adam...
Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ADMA earnings call for the period ending March 31, 2020.
Achieved First Quarter 2020 Total Revenues of $10.2 Million, a 189% Increase Over First Quarter 2019 Strengthened Balance Sheet Through Successful Completion of Underwritten.
Responsive interfaces display a defined and reversible change in physical properties in response to external stimuli. The state of the art in “active” interfaces, which display responsive wettability, permeability, or adhesion is discussed, with a particular …
A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups has come together to support the rapid development of potential new therapie…
In business as in sports, you don’t get to stop training once the season begins. It is during this time of COVID-19 that we small business owners are putting our training to the test.
Colloidal open crystals are attractive materials, especially for their photonic applications. Self-assembly appeals as a bottom-up route for structure fabrication, but self-assembly of colloidal open crystals has proven to be elusive for their mechanical inst…
RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,.